Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration.

Authors :: Jin-Dong Ding
Johnson, Lincoln V.
Herrmann, Roif
Farsiu, Sina
Smith, Stephanie G.
Groelle, Marybeth
Mace, Brian E.
Sullivan, Patrick
Jamison, Jeffrey A.
Kell, Una
Harrabi, Ons
Bollini, Sangeetha Subbarao
Dilley, Jeanette
Kobayashi, Dione
Bing Kuang
Wenlin Li
Pons, Jaume
Lin, John C.
Rickman, Catherine Bowes
Source :: Proceedings of the National Academy of Sciences of the United States of America; 7/12/2011, Vol. 108 Issue 28, p11307-11308, 2p
Publication Year :: 2011
Abstract: The article presents a study on the pathogenic role of Aβ in age-related macular degeneration (AMD) which is the leading cause of irreversible blindness. The study reveals that systemic administration of an anti-β40/42 bispecific antibody aiming the C termini of Aβ40 and Aβ42 conserves retinal function. It shows that treatment with anti-Aβ antibodies has possible therapeutic value in the treatment of advanced and early stages of AMD.

Subjects :: RETINAL degeneration
BLINDNESS
DISEASES in older people
IMMUNOGLOBULINS
PATHOGENIC microorganisms

Language :: English
ISSN :: 00278424
Volume :: 108
Issue :: 28
Database :: Complementary Index
Journal :: Proceedings of the National Academy of Sciences of the United States of America
Publication Type :: Academic Journal
Accession number :: 63150412
Full Text :: https://doi.org/10.1073/pnas.1100901108

Full Text Access

Tools